Continuum of prostate cancer risk for PSA ranges - for ERSPC and PCPT, positive predictive value of TRUS - for prostate cancer detection, Prostate cancer - early detection and screening, Prostate cancer detection and positive predictive value - DRE for different PSA ranges, Prostate cancer incidence - differing between continents and country to country, Prostate cancer screening - prostate cancer incidence increase, Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial, Screening in identifying a disease - stage, treatment applied in order to prevent death or suffering, specific organ marker than tumor marker - since prostatitis, benign prostate hyperplasia (BPH), Stage distribution after PSA or systematic prostate cancer screening
dx.doi.org/10.1002/9781444323146.ch26, hdl.handle.net/1765/82793
no subscription
Erasmus MC: University Medical Center Rotterdam

van Leeuwen, P.J, Roobol-Bouts, M.J, & Schröder, F.H. (2010). Early Detection and Screening for Prostate Cancer. doi:10.1002/9781444323146.ch26